SBOT - Stellar Biotechnologies, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.20
-0.12 (-9.09%)
At close: 3:58PM EDT
Stock chart is not supported by your current browser
Previous Close1.32
Open1.32
Bid1.11 x 1100
Ask1.20 x 900
Day's Range1.10 - 1.32
52 Week Range1.08 - 9.10
Volume149,565
Avg. Volume135,248
Market Cap6.397M
Beta (3Y Monthly)0.02
PE Ratio (TTM)N/A
EPS (TTM)-2.70
Earnings DateFeb 8, 2018 - Feb 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • Zacks Small Cap Researchlast month

    SBOT: NCI Supply Contract: Highlights Growing Interest of KLH for Cancer Immunotherapies

    Securing more KLH supply agreements has been one of Stellar Biotechnologies’ (SBOT) strategic objectives and earlier this month the company made additional headway on that goal. In early September Stellar announced that they entered an agreement with the U.S. National Institutes of Health (NIH) to supply their proprietary KLH for government-sponsored studies.

  • Do Institutions Own Shares In Stellar Biotechnologies Inc (NASDAQ:SBOT)?
    Simply Wall St.last month

    Do Institutions Own Shares In Stellar Biotechnologies Inc (NASDAQ:SBOT)?

    If you want to know who really controls Stellar Biotechnologies Inc (NASDAQ:SBOT), then you’ll have to look at the makeup of its share registry. Insiders often own a large chunkRead More...

  • PR Newswire2 months ago

    Stellar Biotechnologies to Supply KLH to National Institutes of Health

    LOS ANGELES, Sept. 5, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, autoimmune disease and cancers, among other diseases, announced today that it has been contracted by the U.S. National Institutes of Health (NIH) to supply the company's Stellar KLH protein for government-sponsored clinical studies. The company reported that it has initiated product manufacturing for the NIH's National Cancer Institute, which plans to use a vialed formulation of Stellar KLH in dendritic cell-based cancer therapies.

  • PR Newswire2 months ago

    Stellar Biotechnologies to Present at H. C. Wainwright Global Investment Conference

    LOS ANGELES, Aug. 28, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, lupus and cancers, among other diseases, announced today that Stellar CEO and President Frank R. Oakes will present at the H. C. Wainwright 20th Annual Global Investment Conference to be held September 4-6, 2018 in New York City. The company will provide an overview of its Stellar KLH business and recent corporate activities. Based north of Los Angeles at the Port of Hueneme, Stellar Biotechnologies, Inc. (SBOT) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein utilized as a carrier molecule in therapeutic vaccine pipelines (targeting cancers, immune disorders, Alzheimer's and inflammatory diseases) and for assessing immune system function.

  • PR Newswire2 months ago

    Stellar Biotechnologies Reports Third Quarter Financial Results

    LOS ANGELES , Aug. 8, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, ...

  • ACCESSWIRE3 months ago

    Free Pre-Market Technical Pulse on Sesen Bio and Three More Biotech Stocks

    Stock Research Monitor: OGEN, ONCE, and SBOT LONDON, UK / ACCESSWIRE / July 27, 2018 / If you want a free Stock Review on SESN sign up now at www.wallstequities.com/registration . Ahead of today's trading ...

  • Zacks Small Cap Research3 months ago

    SBOT: Neovacs Announces Ph2 Lupus Results, “Will Enable Us To Move Into Ph3…”

    Last week Neovacs announced results of its phase IIb trial investigating safety and efficacy of their IFNa-Kinoid (IFN-K) candidate in the treatment of systemic lupus erythematosus (SLE). While one of the two co-primary endpoints did not reach statistical significance, the other did (and, in fact, was highly statistically significant). In addition, one of the two secondary efficacy endpoints was statistically significant, while the other showed a positive trend towards significance (although did not reach it).

  • Stellar Biotechnologies’ Partner Neovacs’s Favorable Study Data
    Market Realist4 months ago

    Stellar Biotechnologies’ Partner Neovacs’s Favorable Study Data

    Today, Stellar Biotechnologies’ stock was up ~10.5% in premarket trading as the company issued a statement on positive study results published by its partner Neovacs. Neovacs posted favorable Phase 2b study data for IFNalpha Kinoid in patients with moderate to severe lupus or SLE (systemic lupus erythematosus), an autoimmune disease in which healthy tissues come under attack by the immune system. Stellar Biotechnologies provides Keyhole Limpet Hemocyanin (KLH) to Neovacs.

  • PR Newswire4 months ago

    Stellar Issues Statement on Favorable Clinical Study Results

    LOS ANGELES , July 5, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines, today issued a ...

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Stocks to Watch: Heron Therapeutics and Stellar Biotechnologies

    NEW YORK, NY / ACCESSWIRE / June 22, 2018 / Biotech stocks Heron Therapeutics and Stellar Biotechnologies were gaining like wildfire in Thursday’s trading session with both companies releasing positive ...

  • Why Stellar Biotechnologies Saw Pre-Market Gains of 84%
    Market Realist4 months ago

    Why Stellar Biotechnologies Saw Pre-Market Gains of 84%

    Today, Stellar Biotechnologies (SBOT) rose ~84% in the pre-market session on the news of the successful completion of a study related to the company’s KLH (keyhole limpet hemocyanin) products. The study was focused on the molecular composition of these products. The KLH protein is used as a carrier in therapeutic and research applications extensively. The study, which was a quality analysis, was part of the company’s initiatives to support clinical trials of drug candidates in later stages that utilize the KLH protein as a carrier molecule and immunostimulant.

  • Benzinga4 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Casi Pharmaceuticals Inc (NASDAQ: CASI ) stock was ...

  • PR Newswire4 months ago

    Stellar Reports Positive Research Results from KLH Glycosylation Study

    LOS ANGELES, June 21, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, lupus and cancer, among other diseases, today announced the successful completion of a research study focused on the molecular composition of the company's KLH products. The quality analysis was completed as part of Stellar's initiatives to support later stage clinical trials of drug candidates that utilize KLH as a carrier molecule and immunostimulant. As part of the study, third party researchers analyzed the patterns of carbohydrates that attach to the KLH protein through a biologic process known as glycosylation.

  • ACCESSWIRE4 months ago

    Stock Performance Review on Sesen Bio and Three Other Biotech

    LONDON, UK / ACCESSWIRE / June 20, 2018 / If you want a free Stock Review on SESN sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • How Has Stellar Biotechnologies Inc’s (NASDAQ:SBOT) Performed Against The Industry?
    Simply Wall St.5 months ago

    How Has Stellar Biotechnologies Inc’s (NASDAQ:SBOT) Performed Against The Industry?

    After looking at Stellar Biotechnologies Inc’s (NASDAQ:SBOT) latest earnings announcement (31 March 2018), I found it useful to revisit the company’s performance in the past couple of years and assessRead More...

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Stocks to Watch: Recro Pharma and Stellar Biotechnologies

    NEW YORK, NY / ACCESSWIRE / May 25, 2018 / Recro Pharma shares saw a huge drop and hit a new low after the FDA declined to approve the company's IV meloxicam, which was supposed to be the company's first ...

  • PR Newswire5 months ago

    Stellar Biotechnologies Announces Exercise of Warrants Resulting in Cash Proceeds of $3 Million

    LOS ANGELES , May 24, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT, "Stellar" or the "Company"), a leading manufacturer of a key protein utilized in multiple immunotherapy ...

  • PR Newswire5 months ago

    Stellar Achieves Robust Viral Clearance for Manufacturing Process

    LOS ANGELES, May 24, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, lupus and cancer, among other diseases, today announced that third-party trial results have demonstrated that the company's KLH manufacturing methods achieve robust viral clearance. This clearance step is a key quality assurance milestone under Stellar's initiatives to increase the scalability and throughput capacity of its manufacturing processes. Results from testing completed by Texcell, a contract testing organization for viral safety, demonstrated that Stellar's manufacturing process for its most widely used formulation effectively removes three representative viruses, and meets suggested regulatory criteria for robustness.

  • PR Newswire5 months ago

    Stellar Biotechnologies Announces Closing of $5.5 Million Public Offering

    LOS ANGELES, May 15, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, lupus and cancers, among other diseases, announced today the completion of its previously announced public offering of 2,075,472 units (the "Units"), with each Unit consisting of (i) one common share, no par value per share (the "Common Shares") or Common Share equivalent, and (ii) one warrant to purchase one Common Share for aggregate gross proceeds of $5.5 million. The offering was priced at $2.65 per Common Share (or Common Share equivalent), with each Common Share (or Common Share equivalent) sold with one five-year warrant to purchase one Common Share, at an exercise price of $2.65.

  • Zacks Small Cap Research5 months ago

    SBOT: Q2 2018 Financial Results/Update: Neovacs reiterates Ph2 Lupus data expected in June

    Revenue, which was just about dead-on with our estimate, remains at relatively very low levels, reflecting the conclusion of several mid-stage clinical trials that SBOT supported via supply of KLH. Additionally, an eventual supply agreement for a commercialized product (potentially such as Neovacs’ IFNa-Kinoid candidate) would likely significantly steepen the revenue curve. As we have noted in the recent past, while revenue has largely been negligible, we had anticipated as much given that current demand is dependent on timing of activity of the company’s clinical trial customers.

  • Benzinga5 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Trade Desk Inc (NASDAQ: TTD ) stock soared nearly ...

  • CNW Group5 months ago

    Stellar Biotechnologies Announces Pricing of $5.5 Million Public Offering

    LOS ANGELES , May 11, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, lupus and cancers, among other diseases, today announced the pricing of a public offering of an aggregate of 2,075,472 units (the "Units"), with each Unit consisting of (i) one common share, no par value per share (the "Common Shares") or Common Share equivalent, and (ii) one warrant to purchase one Common Share (the "Warrants"). H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The Common Shares or Common Share equivalents and the accompanying Warrants can only be purchased together in this offering but will be issued separately.

  • PR Newswire5 months ago

    Stellar Biotechnologies Announces Pricing of $5.5 Million Public Offering

    LOS ANGELES, May 11, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, lupus and cancers, among other diseases, today announced the pricing of a public offering of an aggregate of 2,075,472 units (the "Units"), with each Unit consisting of (i) one common share, no par value per share (the "Common Shares") or Common Share equivalent, and (ii) one warrant to purchase one Common Share (the "Warrants"). H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The Common Shares or Common Share equivalents and the accompanying Warrants can only be purchased together in this offering but will be issued separately.

  • PR Newswire5 months ago

    Stellar Biotechnologies Reports Second Quarter Financial Results

    LOS ANGELES , May 7, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, ...

  • PR Newswire7 months ago

    Stellar Biotech Begins Scale-Up and Expansion Project at Port Facility

    LOS ANGELES, March 29, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, lupus and cancers, among other diseases, initiated the second phase of an expansion project at the Port of Hueneme, north of Los Angeles, California. The construction project will allow the company to expand production of a medical-grade protein, called KLH, which Stellar produces in aquaculture from a marine mollusk. The plan includes 10,000 square feet of renovated Pacific ocean-front space for aquaculture production and related activities as well as new protective structures and aesthetic improvements.